Glenmark Pharmaceuticals Ltd announced consolidated revenue of INR 39,600 million for the third quarter of fiscal year 2026, marking a 15.1% increase compared to the same period last year. The company’s India formulation sales rose by 22.1% to INR 12,986 million. North America revenue, which includes out-licensing income, reached INR 9,706 million for the quarter.
Revenue from Europe also showed growth, contributing to the overall positive performance. These results reflect continued expansion across Glenmark’s key markets during the quarter.
**Why this matters**
The revenue growth highlights Glenmark’s strengthening position in both domestic and international markets. Increased sales in India and North America suggest successful market strategies and product acceptance, which could support the company’s future financial performance.
Source: NewsData